AB Science reports its revenues for the year 2023 and provides an update on its activities
PRESS RELEASE…
2,075€
-6,32%
Echtzeit-Aktienkurs AB SCIENCE S.A. EO-,01
Bid:
Ask:
Nachrichten zur AB SCIENCE S.A. EO-,01 Aktie
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
PRESS RELEASE…
AB Science announces a slight delay in the publication of its 2023 annual financial report
PRESS RELEASE…
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
PRESS RELEASE…
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
PRESS RELEASE…
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
PRESS RELEASE…
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
PRESS RELEASE…
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
PRESS RELEASE…
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
PRESS RELEASE…
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
PRESS RELEASE…
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
PRESS RELEASE…
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
PRESS RELEASE…
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
PRESS RELEASE…
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
PRESS RELEASE…
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
PRESS RELEASE...…
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
PRESS RELEASE...…
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
...…
AB Science reports its revenues for the year 2022 and provides an update on its activities
PRESS RELEASE...…
AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
PRESS RELEASE...…
AB Science announces the implementation of a new strategy and the launch of a capital increase
PRESS RELEASE...…
AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
...…
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
PRESS RELEASE...…
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
PRESS RELEASE...…
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
PRESS RELEASE...…
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE...…
$3.89 Billion Worldwide Canine Atopic Dermatitis Industry to 2027 - Key Players Include AB Science, Bimeda, Bioceltix, Boehringer Ingelheim International and Ceva Sante Animale
DUBLIN, Jan. 11, 2023 /PRNewswire/ -- The "Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast…
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis
PRESS RELEASE...…
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE...…
AB Science Gets Canada Request for Additional Information for Masitinib New Drug Submission
AB Science Gets Canada Request for Additional Information for Masitinib New Drug Submission...…
AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
PRESS RELEASE...…